{"id":"NCT00097695","sponsor":"Shire","briefTitle":"Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema","officialTitle":"Randomized, Double Blind, Placebo-Controlled, Multicenter Study of a Subcutaneous Formulation of Icatibant for the Treatment of Hereditary Angioedema","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-12-28","primaryCompletion":"2006-07-17","completion":"2006-07-17","firstPosted":"2004-11-29","resultsPosted":"2013-12-24","lastUpdate":"2021-06-09"},"enrollment":84,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Angioedema"],"interventions":[{"type":"DRUG","name":"Icatibant","otherNames":["Brand name, FirazyrÂ®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Icatibant- Randomized","type":"EXPERIMENTAL"},{"label":"Placebo-Randomized","type":"PLACEBO_COMPARATOR"},{"label":"Controlled Open-label / laryngeal attack","type":"EXPERIMENTAL"},{"label":"Untreated Patients at the baseline","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the efficacy and safety of Icatibant, a bradykinin antagonist in the treatment of acute cutaneous and/or abdominal attacks in patients with hereditary angioedema (HAE).","primaryOutcome":{"measure":"Time to Onset of Symptom Relief (TOSR)","timeFrame":"5 days","effectByArm":[{"arm":"Randomized -Icatibant","deltaMin":2.5,"sd":null},{"arm":"Randomized -Placebo","deltaMin":4.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.142"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["24749847","20818888"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":27},"commonTop":["Hereditary angioedema","Infections","Administration site conditions","Headache/Migraine","Nausea"]}}